RT Journal Article
T1 Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.
A1 López-Cano, Carolina
A1 Ciudin, Andreea
A1 Sánchez, Enric
A1 Tinahones, Francisco J
A1 Barbé, Ferran
A1 Dalmases, Mireia
A1 García-Ramírez, Marta
A1 Soto, Alfonso
A1 Gaeta, Anna Michela
A1 Pellitero, Silvia
A1 Martí, Raquel
A1 Hernández, Cristina
A1 Simó, Rafael
A1 Lecube, Albert
AB To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s
YR 2022
FD 2022
LK http://hdl.handle.net/10668/20499
UL http://hdl.handle.net/10668/20499
LA en
DS RISalud
RD Apr 9, 2025